COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.
Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.
COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.
Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.
Get expert clinical insights, study design support, and statistical analysis.
Explore our collection of clinical research, recent press, podcasts, and more.
The real world is an unpredictable place. It can be messy and confusing, full of challenges and uncertainties that have to be overcome before we can move forward with confidence and clarity…
September is Blood Cancer Awareness Month, a time to bring extra attention to the more than 1.6 million people living with leukemia, lymphoma, myeloma, and other hematological cancers. These cancers can strike…
COTA Spokesperson: C.K. Wang, Chief Medical Officer Panalgo Spokesperson: Meg Richards, PhD, MPH, Executive Director of Scientific Strategy Abbreviated answers Q: What is the value of real-world data for accurate healthcare analytics…
Partner with COTA for the highest-quality curated cancer patient datasets.
